EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MiMedx Group's enterprise value is $925.4 Mil.
MiMedx Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $40.4 Mil. Therefore, MiMedx Group's EV-to-EBITDA for today is 22.90.
The historical rank and industry rank for MiMedx Group's EV-to-EBITDA or its related term are showing as below:
MDXG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1316 Med: -14.79 Max: 420.25
Current: 22.9
During the past 13 years, the highest EV-to-EBITDA of MiMedx Group was 420.25. The lowest was -1316.00. And the median was -14.79.
MDXG's EV-to-EBITDA is ranked worse than 72.36% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs MDXG: 22.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), MiMedx Group's stock price is $6.43.
MiMedx Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.380. Therefore, MiMedx Group's PE Ratio for today is 16.92.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
MiMedx Group EV-to-EBITDA Historical Data
The historical data trend for MiMedx Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MiMedx Group's EV-to-EBITDA
For the Biotechnology subindustry, MiMedx Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MiMedx Group's EV-to-EBITDA falls into.
MiMedx Group EV-to-EBITDA Calculation
MiMedx Group's EV-to-EBITDA for today is calculated as:
MiMedx Group's current Enterprise Value is $925.4 Mil.
MiMedx Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (NAS:MDXG) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
MiMedx Group's PE Ratio for today is calculated as:
MiMedx Group's share price for today is $6.43.
MiMedx Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.380.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of MiMedx Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MDXG has been successfully added to your 